Abstract
Objectives
This study evaluated the long-term outcomes of intensity-modulated radiation therapy (IMRT) combined with short-term neoadjuvant androgen deprivation therapy (ADT) in patients with intermediate-risk (IR) prostate cancer (PCa).
Materials and methods
Patients with IR PCa treated with IMRT at our institution between September 2000 and November 2010 were analyzed retrospectively. The treatment consisted of IMRT (70–78 Gy in 35–39 fractions) combined with 6 months of neoadjuvant ADT. Salvage ADT was initiated when the prostate-specific antigen level was > 4.0 ng/mL
Results
In total, 106 consecutive patients with IR PCa (median age: 70 years old) were analyzed. The median follow-up period was 8.0 years. The overall survival, PCa-specific survival, biochemical failure, and clinical failure rates were 99.0%, 100.0%, 6.8%, and 1.9% at 5 years and 89.1%, 100.0%, 11.3%, and 2.9% at 10 years, respectively. Late recurrence (> 5 years) was observed in three cases (2.8%). The cumulative incidence rates of genitourinary (GU) and gastrointestinal (GI) toxicities (grade 2/3) were 10.5% and 5.8% at 5 years, and 14.7% and 5.8% at 10 years, respectively. No patient developed grade 4/5 GU toxicities or grade 3–5 GI toxicities.
Conclusion
IMRT at a dose up to 78 Gy combined with short-term neoadjuvant ADT resulted in excellent long-term disease-free outcomes with acceptable morbidities among patients with IR PCa. In addition, the incidence of late recurrence was very low. Further investigation is warranted to confirm our findings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alicikus ZA, Yamada Y, Zhang Z et al (2011) Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 117(7):1429–1437. https://doi.org/10.1002/cncr.25467
National Comprehensive Cancer network (2019) NCCN Guidelines; prostate cancer version 2.2019. In: The category of prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostatepdf. Accessed 17 Apr 2019
Zaorsky NG, Palmer JD, Hurwitz MD et al (2015) What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115(3):295–300. https://doi.org/10.1016/j.radonc.2015.05.011
Pasalic D, Kuban DA, Allen PK et al (2019) Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys 104(4):790–797. https://doi.org/10.1016/j.ijrobp.2019.02.045
Dearnaley DP, Jovic G, Syndikus I et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15(4):464–473. https://doi.org/10.1016/S1470-2045(14)70040-3
Heemsbergen WD, Al-Mamgani A, Slot A et al (2014) Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110(1):104–109. https://doi.org/10.1016/j.radonc.2013.09.026
Bolla M, Maingon P, Carrie C et al (2016) Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol 34(15):1748–1756. https://doi.org/10.1200/JCO.2015.64.8055
Michalski JM, Moughan J, Purdy J et al (2018) Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol 4(6):e180039. https://doi.org/10.1001/jamaoncol.2018.0039
Abu-Gheida I, Reddy CA, Kotecha R et al (2019) Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 104(2):325–333. https://doi.org/10.1016/j.ijrobp.2019.01.091
Spratt DE, Zumsteg ZS, Ghadjar P et al (2014) Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 114(3):360–367. https://doi.org/10.1111/bju.12514
Mizowaki T, Norihisa Y, Takayama K et al (2016) Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c–T2N0M0 prostate cancer. Int J Clin Oncol 21(4):783–790. https://doi.org/10.1007/s10147-016-0954-4
Zhu S, Mizowaki T, Nagata Y et al (2005) Comparison of three radiotherapy treatment planning protocols of definitive external-beam radiation for localized prostate cancer. Int J Clin Oncol 10(6):398–404. https://doi.org/10.1007/s10147-005-0519-4
Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244
Wilcox SW, Aherne NJ, McLachlan CS et al (2015) Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series. J Med Imaging Radiat Oncol 59(1):125–133. https://doi.org/10.1111/1754-9485.12275
Zelefsky MJ, Kollmeier M, Cox B et al (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84(1):125–129. https://doi.org/10.1016/j.ijrobp.2011.11.047
Engels B, Soete G, Gevaert T et al (2014) Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer. Radiother Oncol 111(1):106–109. https://doi.org/10.1016/j.radonc.2014.02.009
Pisansky TM, Hunt D, Gomella LG et al (2015) Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 33(4):332–339
Aizawa R, Takayama K, Nakamura K et al (2019) Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Int J Clin Oncol 24(10):1247–1255. https://doi.org/10.1007/s10147-019-01478-y
Cooperberg MR, Hinotsu S, Namiki M et al (2016) Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 117(1):102–109. https://doi.org/10.1111/bju.12937
Acknowledgements
This work was supported, in part, by JSPS KAKENHI Grant number 16K10390. The funding programs had no effects on the study design, analysis, and interpretation of the data of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Aizawa, R., Takayama, K., Nakamura, K. et al. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol 25, 713–719 (2020). https://doi.org/10.1007/s10147-019-01596-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-019-01596-7